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EDITORIAL
The  pertussis  problem:  classical  epidemiology  and
strain characterization  should  go  hand  in  hand,
O  problema  da  coqueluche:  a  caracterizac¸ão  da  epidemiologia  clássica  e  da
cepa  deve  ser  feita  por  todos
Frits R. Mooi ∗, Anne Zeddeman, Marjolein van Gent
Centre  for  Infectious  Disease  Control,  National  Institute  for  Public  Health  and  the  Environment,  Bilthoven,  Netherlands
In  this  issue  of  Jornal  de  Pediatria,  Torres  et  al.1 present
a  study  on  the  incidence,  clinical  features,  mortality,  and
vaccination  status  of  patients  with  whooping  cough  in  the
state  of  Paraná,  in  the  period  of  2007  to  2013.  They  also
provide  genotypic  data  on  the  B.  pertussis  strains  isolated.
The  study  shows  that  pertussis  in  Paraná  is  on  the  increase,
and  that  most  severe  symptoms  and  deaths  occur  in  children
younger  than  2  months  of  age.  The  combination  of  classical
epidemiology  -- which  focuses  on  incidences,  age  distribu-
tion,  and  clinical  features  --  with  strain  characterization  is
an  important  aspect  of  this  paper,  as  only  this  combination
allows  us  to  fully  understand  the  causes  for  the  resurgence
of  pertussis.
Pertussis  is  on  the  increase  across  the  world  and,  as
the  authors  note,  part  of  this  increase  is  due  to  enhanced
awareness  among  clinicians  and  improved  detection  through
the  introduction  of  polymerase  chain  reaction  (PCR).  These
two  factors  have  resulted  in  a  more  accurate  assessment
of  the  disease  burden,  which  has  tended  to  be  underesti-
mated.  The  increased  accuracy  of  pertussis  diagnosis  has
led  some  authors  to  suggest  that  the  resurgence  of  per-
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tussis  is  an  artifact.  However,  current  knowledge  supports
the  assumption  that  there  is  a  real  increase  in  pertussis,
mainly  caused  by  two  factors:  waning  of  vaccine-induced
immunity  and  adaptation  of  the  pathogen  by  mutations  in
its  DNA.  The  two  factors  are  not  independent,  as  pathogen
adaptation  reduces  the  period  in  which  vaccines  are  effec-
tive  and  thereby  increases  the  speed  in  which  protective
immunity  wanes  (see  below).  Hence,  waning  immunity  and
pathogen  adaptation  are  two  sides  of  the  same  coin.2 Recent
studies  indicate  that  the  switch  from  whole  cell  vaccines
(WCVs)  to  acellular  vaccines  (ACVs)  has  also  contributed
to  the  resurgence  of  pertussis,  because  immunity  induced
by  ACVs  is  of  shorter  duration  compared  to  WCVs.3,4 It
should  be  noted,  however,  that  resurgence  of  pertussis
is  also  observed  in  countries  which  have  retained  WCVs,
underlining  again,  that  multiple  factors  are  involved  (this
study).5,6
Pathogens  do  not  only  become  resistant  against  antibi-
otics,  but  also  against  vaccines.  However,  the  latter  process
is  subtler,  because  vaccine  resistance  accrues  in  small  steps
and  may  therefore  (initially)  go  unnoticed.  Further,  vaccine
resistance  is  not  absolute  and  does  not  imply  that  B.  per-
tussis  is  able  to  cause  disease  in  a  highly  immune  host.  The
effect  is  less  pronounced,  in  that  adapted  strains  are  able  to
infect  hosts  at  a  higher  level  of  immunity  (i.e.  earlier  after
vaccination)  compared  to  non-adapted  strains.  Obviously,
this  results  in  an  increase  in  susceptible  persons  and  thus  in
pathogen  circulation.
Although  studies  in  mice  have  shown  that  pathogen  adap-
tation  affects  vaccine  efﬁcacy,  such  effects  are  difﬁcult  to
establish  in  human  populations,  as  they  require  long-term
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studies  with  large  populations.  Therefore,  it  is  important
to  analyze  the  nature  of  the  genetic  adaptations  in  order
to  assess  if  they  are  expected  to  affect  vaccine  efﬁcacy.  In
general  this  is  the  case  with  B.  pertussis.  The  ﬁrst  adap-
tations  in  B.  pertussis  involved  relatively  small  changes
in  surface  proteins  known  to  induce  protective  immunity:
pertussis  toxin  (Ptx),  pertactin  (Prn),  and  ﬁmbriae.2 Later,
changes  in  gene  regulation  were  found,  which  resulted  in  an
increased  production  of  several  virulence  factors  including
Ptx  and  proteins  involved  in  complement  resistance.7,8 Such
changes  may  result  in  increased  immune  suppression  and
immune  evasion.  The  strains  showing  increased  production
of  virulence  factors  belong  to  the  so-called  P3  (or  ptxP3)
lineage,  which  has  recently  spread  worldwide  and  predom-
inates  in  many  vaccinated  populations.9,10 Increases  in  the
prevalence  of  P3  strains  have  been  associated  with  increased
notiﬁcation  in  the  Netherlands  and  Australia.7,11 A  study,
using  pulsed-ﬁeld  gel  electrophoresis  (PFGE)  to  type  Brazil-
ian  strains,  identiﬁed  two  proﬁles  which  are  found  among  P3
strains  circulating  in  the  US,12,13 suggesting  that  P3  strains
are  also  present  in  Brazil.  Indeed,  the  genome  sequence  of
a  Brazilian  P3  strain  has  recently  been  published.14
The  most  recent  adaptation  of  B.  pertussis  involves  the
loss  of  the  production  of  Prn,  a  component  of  most  ACVs.
Prn-deﬁcient  strains  predominate  in  a  number  of  countries
in  which  ACVs  have  been  used  for  many  years.15,16 Interest-
ingly,  Prn-deﬁcient  strains  have  not  been  observed  in  Poland,
which  uses  a  WCV.17 This  suggests  that  the  introduction  of
ACVs  has  selected  for  Prn-deﬁcient  strains,  and  that  their
emergence  can  be  prevented  by  the  use  of  vaccines  which
provide  a  broad  immunity.  It  would  be  interesting  to  deter-
mine  if  Prn-deﬁcient  strains  circulate  in  Brazil.
How  could  the  study  performed  by  Torres  et  al.1 be
improved?  It  must  be  realized  that  there  will  always  be  local
constraints  such  as  lack  of  funds,  equipment,  and  exper-
tise.  Thus,  this  is  not  a  criticism,  but  an  attempt  to  paint
the  ideal  picture.  One  suggestion  is  to  use  a  typing  method
which  allows  for  international  comparisons.  By  sequencing
polymorphic  regions  in  the  genes  for  the  Ptx  A  subunit,  the
Ptx  promoter  (ptxP), Prn,  and  Fim3,  important  characteris-
tics  of  current  strains  can  be  determined.18 Of  course,  the
vaccine  strain  should  be  included  to  determine  the  extent
of  divergence  with  circulating  strains.  PFGE  is  also  useful
to  type  strains,  but  requires  careful  standardization  and
does  not  always  reveal  true  genetic  relationships.19 Single
nucleotide  polymorphism  (SNP)  typing  has  the  discrimina-
tory  power  of  PFGE,  is  unequivocal,  and  reveals  true  genetic
relationships.  We  have  recently  developed  an  economical,
high-throughput  SNP  typing  method.20
To  solve  the  pertussis  problem,  it  is  necessary  to  distin-
guish  between  short-term  and  long-term  approaches.  In  the
long  term,  we  need  to  develop  pertussis  vaccines  that  induce
longer-lasting  immunity.  In  the  short  term,  introduction  of
maternal  vaccination  can  substantially  decrease  morbidity
and  mortality.  Studies  in  the  UK  have  shown  that  mater-
nal  vaccination  is  very  effective  (estimated  vaccine  efﬁcacy
90%)  and  safe  for  mother  and  child.21,22 As  many  studies  have
shown,  including  the  study  by  Torres  et  al.,  most  severe
pertussis  and  mortality  occurs  in  infants  younger  than  2-
3  months.  If  this  category  can  be  protected  by  maternal
vaccination  until  the  primary  series  have  started,  the  most
signiﬁcant  part  of  the  pertussis  problem  may  be  solved.
The  question  that  should  then  be  addressed  is  whether  the
pertussis  burden  in  adolescents,  adults,  and  the  elderly  is
severe  enough  to  merit  using  limited  resources  in  order  to
develop  better  pertussis  vaccines.
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